U.S. Drug of Abuse (DoA) Testing Market

Industry Overview

The U.S. Drug of Abuse (DoA) Testing Market is expected to grow at a CAGR of 9.7% during the forecast period with its market size predicted to reach USD 4.6 billion by 2030. The U.S. DoA testing market is primarily driven by the stringent laws and regulations, government initiatives, and increasing awareness against drug abuse and development of advanced drug test equipment. The testing for drug abuse requires products such as immunoassay analyzers, chromatography instruments, breath analyzers, rapid test kits, and assay kits & reagents.

Market Segmentation

Insight by Product

Among the various products being used for testing drug abuse, the rapid test kits account for the largest demand in the U.S. DoA testing industry. The high demand for these kits is primarily due to the need for easily available and accessible testing for on the spot drug abuse testing. The rapid test kits as per its name also present output in a short time thereby has higher demand in comparison to the other product category. The market for breath analyzers is expected to grow at the highest CAGR during the forecast period.

Insight by Sample Type

The DOA tests make use of human samples such as urine, saliva, hair, blood, breath, and others. Urine is majorly used for drug abuse testing since it contains parent drugs or metabolites in them, that is tested for the presence of major illicit drugs. The urine samples lead the global Drug of Abuse (DOA) testing market based on size. Some of the other sample type used includes tissue and sweat.

Insight by End User

Hospitals are the largest end user for the DoA products and are also estimated to retain the largest market size during the forecast period. The category’s large size is due to the increasing number of research and drug test being conducted. The hospitals account to hold high number of tests due to the availability of products on a large scale as compared to other end users of DOA testing. Also, the presence of number of clinicians in hospitals is larger, marking its large share over others.

U.S. Drug of Abuse (DoA) Testing Market Report Coverage

Industry Dynamics

Growth Drivers

The stringent laws and regulations, government initiatives to curb drug abuse, and increasing awareness against drug abuse and development of advanced drug test equipment are the primary growth drivers for the U.S. DoA testing industry. The substance misuse and its addiction of opioids such as morphine and heroin have been a serious concern for the U.S. government as it affects the socio-economic welfare and public healthcare. The National Institute on Drug Abuse reported that an estimated 1.9 million people in the United States suffered from substance use disorders related to prescription opioid pain medicines in 2013 and 517,000 suffered from a heroin use disorder.

The government in the country is promoting educational initiatives to be delivered in school and communities, supporting prescription drug monitoring programs, implementing overdose education and naloxone distribution programs, and aggressive law enforcement efforts. The government is also supporting the investment for research and development for pain management and next-generation analgesics. This is anticipated fuel the market for DoA testing in the U.S.

Challenges

The legalization of certain drugs and inability to detect low dose modified drugs are the key challenges faced by the U.S. DoA testing industry.

Competitive Insight

Some of the key players operating in the U.S. DoA testing market are Siemens AG, Danaher Corporation, Merck KGaA, Laboratory Corporation of America Holdings, Express Diagnostics Int'l, Inc., Quest Diagnostics Inc., Waters Corporation, Abbott Laboratories, Psychemedics Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche AG.

The U.S. Drug of Abuse (DoA) Testing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.

Segments Covered in the Report

• By Product 
  • Immunoassay Analyzers
  • Chromatography Instruments
  • Breath Analyzers
  • Rapid Test Kits
  • Assay Kits & Reagents
  • Others
• By Sample Type
  • Urine
  • Saliva
  • Hair
  • Blood
  • Breath
  • Others
• By End-User 
  • Hospitals
  • Diagnostic laboratories
  • On-the-spot Testing
  • Forensic Laboratories
  • Others

PRIMARY RESEARCH INTERVIEWS - BREAKDOWN

1. Research Overview 

  1.1. The Report Offers

  1.2. Market Coverage

    1.2.1. By Product

    1.2.2. By Sample Type

    1.2.3. By End User

  1.3. Research Phases

  1.4. Limitations

  1.5. Market Size Estimations and Forecast

    1.5.1. Data Sources

      1.5.1.1. Primary Research

      1.5.1.2. Secondary Research

    1.5.2. Methodology

      1.5.2.1. Data Exploration

      1.5.2.2. Forecast Parameters

      1.5.2.3. Data Validation

      1.5.2.4. Assumptions

    1.5.3. Study Period & Data Reporting Unit

2. Executive Summary

3. Market Definition

  3.1. By Product

    3.1.1. Immunoassay Analyzers

    3.1.2. Chromatography Instrument

    3.1.3. Breath Analyzers

    3.1.4. Rapid Test Kits

    3.1.5. Assay Kits & Reagents

    3.1.6 Others

  3.2. By Sample Type

    3.2.1. Urine

    3.2.2. Saliva

    3.2.3. Hair

    3.2.4. Blood

    3.2.5. Breath

    3.2.6. Others

  3.3. By End User

    3.3.1. Hospitals

    3.3.2. Diagnostic laboratories

    3.3.3. On-the-spot Testing

    3.3.4. Forensic Laboratories

    3.3.5. Others

4. Industry Overview

  4.1. Industry Dynamics

    4.1.1. Market Growth Drivers

    4.1.2. Market Growth Restraints

    4.1.3. Key Market Trends

    4.1.4. Major Opportunities

  4.2. Industry Ecosystem

    4.2.1. Porter’s Five Forces Analysis

    4.2.2. Recent Development Analysis

    4.2.3. Value Chain Analysis

  4.3. Competitive Insight

    4.3.1. Competitive Position of Industry Players

    4.3.2. Market Attractive Analysis

5. U.S. Market Estimate and Forecast

  5.1. By Product 

  5.2. By Sample Type

  5.3. By End User

6. Company Profiles

  6.1. Siemens AG

    6.1.1. Snapshot

    6.1.2. Overview

    6.1.3. Offerings

    6.1.4. Financial Insight

    6.1.5. Recent Developments

  6.2. Danaher Corporation

    6.2.1. Snapshot

    6.2.2. Overview

    6.2.3. Offerings

    6.2.4. Financial Insight

    6.2.5. Recent Developments

  6.3. Merck KGaA

    6.3.1. Snapshot

    6.3.2. Overview

    6.3.3. Offerings

    6.3.4. Financial Insight

    6.3.5. Recent Developments

  6.4. Laboratory Corporation of America Holdings

    6.4.1. Snapshot

    6.4.2. Overview

    6.4.3. Offerings

    6.4.4. Financial Insight

    6.4.5. Recent Developments

  6.5. Express Diagnostics Int'l, Inc.

    6.5.1. Snapshot

    6.5.2. Overview

    6.5.3. Offerings

    6.5.4. Financial Insight

    6.5.5. Recent Developments

  6.6. Quest Diagnostics Inc.

    6.6.1. Snapshot

    6.6.2. Overview

    6.6.3. Offerings

    6.6.4. Financial Insight

    6.6.5. Recent Developments

  6.7. Waters Corporation

    6.7.1. Snapshot

    6.7.2. Overview

    6.7.3. Offerings

    6.7.4. Financial Insight

    6.7.5. Recent Developments

  6.8. Abbott Laboratories

    6.8.1. Snapshot

    6.8.2. Overview

    6.8.3. Offerings

    6.8.4. Financial Insight

    6.8.5. Recent Developments

  6.9. Psychemedics Corporation 

    6.9.1. Snapshot

    6.9.2. Overview

    6.9.3. Offerings

    6.9.4. Financial Insight

    6.9.5. Recent Developments

  6.10. Bio-Rad Laboratories, Inc.

    6.10.1. Snapshot

    6.10.2. Overview

    6.10.3. Offerings

    6.10.4. Financial Insight

    6.10.5. Recent Developments

  6.11. Thermo Fisher Scientific Inc.

    6.11.1. Snapshot

    6.11.2. Overview

    6.11.3. Offerings

    6.11.4. Financial Insight

    6.11.5. Recent Developments

  6.12. F. Hoffmann-La Roche AG

    6.12.1. Snapshot

    6.12.2. Overview

    6.12.3. Offerings

    6.12.4. Financial Insight

    6.12.5. Recent Developments

7. Appendix

  7.1. Exchange Rates

  7.2. Abbreviations

Note: Financial insight and recent developments of different companies are subject to availability of information in secondary domain.

List of Tables

Table 1 Sources
Table 2 Study Periods
Table 3 Data Reporting Unit
Table 4 U.S. DoA Testing Market Size, by Product, 2018 – 2023 (USD Billion)
Table 5 U.S. DoA Testing Market Size, by Product, 2025 – 2030 (USD Billion)
Table 6 U.S. DoA Testing Market Size, by Sample Type, 2018 – 2023 (USD Billion)
Table 7 U.S. DoA Testing Market Size, by Sample Type, 2025 – 2030 (USD Billion)
Table 8 U.S. DoA Testing Market Size, by End-User, 2018 – 2023 (USD Billion)
Table 9 U.S. DoA Testing Market Size, by End-User, 2025 – 2030 (USD Billion)
Table 10 Snapshot – Siemens AG
Table 11 Snapshot – Danaher Corporation
Table 12 Snapshot – Merck KGaA
Table 13 Snapshot – Laboratory Corporation of America Holdings
Table 14 Snapshot – Express Diagnostics Int'l, Inc.
Table 15 Snapshot – Quest Diagnostics Inc.
Table 16 Snapshot – Waters Corporation
Table 17 Snapshot – Abbott Laboratories
Table 18 Snapshot – Psychemedics Corporation
Table 19 Snapshot – Bio-Rad Laboratories, Inc
Table 20 Snapshot – Thermo Fisher Scientific Inc.
Table 21 Snapshot – F. Hoffmann-La Roche AG

List of Figures

Figure 1  Market Coverage
Figure 2  Research Phases
Figure 3  Secondary Sources for Different Parameters
Figure 4  Methodology
Figure 5  Data Mining & Exploration
Figure 6  Data Triangulation
Figure 7  Assumptions for Market Estimation and Forecast
Figure 8  Executive Summary
Figure 9  U.S. DoA Testing Market - Growth Drivers and Restraints
Figure 10 Porter’s Five Forces Analysis
Figure 11 Competitive Benchmark
Figure 12 U.S. DoA Testing Market Highlight
Figure 13 U.S. DoA Testing Market Size, by Product, 2018 – 2030 (USD Billion)
Figure 14 U.S. DoA Testing Market Size, by Sample Type, 2018 – 2030 (USD Billion)
Figure 15 U.S. DoA Testing Market Size, by End-User, 2018 – 2030 (USD Billion)